Lipitor, best-selling drug ever, goes off patent
Lipitor, the top-selling drug that lowers LDL cholesterol (the bad kind) will cease being Pfizer’s cash cow as of Wednesday.
The brand-name drug will still be available, but now patients can ask for the less-expensive generic version, called atorvastin. Lipitor generated more than $100 billion in revenue for Pfizer since it was approved in 1997.
Patients need not fear that generic atorvastatin will be an inferior medication. According a 2010 study in the journal Clinical Therapeutics, patients receiving Lipitor in an eight-week study had a 48% reduction in LDL cholesterol compared to a 44% reduction among people taking the generic. The difference is not statistically significant.
Lipitor costs patients about $160 per month while generic statins typically cost about $10 per month. It’s not clear yet, however, what generic versions of the medication will cost.
The Food and Drug Administration has more information.
Lipitor is the first in a surge of blockbuster medications that will come off patent in the coming year, according to a article in the journal Managed Care. In 2012, patents will expire on Diovan, Lexapro, Actos, Singulair, Seroquel and Plavix.
Return to Booster Shots blog.
Follow me: twitter.com/LATShariRoan
Get our free Coronavirus Today newsletter
Sign up for the latest news, best stories and what they mean for you, plus answers to your questions.
You may occasionally receive promotional content from the Los Angeles Times.